This finding has significant translational implications for the personalized management of tumour-associated epilepsy, as targeted mu/IDH1 inhibitors could potentially ameliorate antiepileptic treatment in patients with mu/IDH1 gliomas (Figure 1). This evidence concerns the gene IDH1 and central nervous system cancer.